FDA Approves Zunveyl (benzgalantamine) for the Treatment of Alzheimer's Disease
FDA approves Zunveyl (benzgalantamine) for mild-to-moderate Alzheimer's disease, a novel oral therapy with a dual mechanism of action designed to improve tolerability and efficacy, addressing therapy adherence issues due to GI side effects and insomnia.
Highlighted Terms
Related News
FDA Approves Zunveyl (benzgalantamine) for the Treatment of Alzheimer's Disease
FDA approves Zunveyl (benzgalantamine) for mild-to-moderate Alzheimer's disease, a novel oral therapy with a dual mechanism of action designed to improve tolerability and efficacy, addressing therapy adherence issues due to GI side effects and insomnia.